VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

• click to rate

  Posted by Two Blokes Apr 15 - Filed in Stock - 7 views
  
  Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.